Floatz logo

Dordaviprone

Carcinosarcoma

UNC Lineberger Comprehensive Cancer CenterSmall moleculePhase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Carcinosarcoma cohort.

Asset / SponsorPhaseRating
Carboplatin
Blueprint Medicines Corporation
Phase 3BB
Ifosfamide
GOG Foundation
Phase 3B
Dkn-01
Leap Therapeutics, Inc.
Phase 2B
Nivolumab
Instituto do Cancer do Estado de São Paulo
Phase 2CCC
Pamiparib
Australia New Zealand Gynaecological Oncology Group
Phase 2CCC

View all 12 →

Same molecule, other indications

Dordaviprone is also rated in:

triple-negative breast carcinomaDormant
CCC
Indicative ·
51 / 100
View asset →
glioblastomaDormant
CCC
Indicative ·
48 / 100
View asset →
triple-negative breast carcinomaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →